The FDA classified the recall of Vitruvias’ 30 mg Thyroid Tablets, USP, as Class I because they may be stronger than intended. Lot 504950 was distributed nationwide; about 1,900 units were sold, and patients taking them should contact their provider.
The FDA says a Class I recall indicates that use of the product is likely to cause serious health effects or death. The recalled tablets are not levothyroxine or Synthroid, which are dosed in micrograms; a separate levothyroxine recall a few months earlier may have added to confusion. Endocrinologist Jared Friedman said risks from taking too much thyroid hormone can include fatigue, unintended weight loss, rapid heart rate or arrhythmias.
The product can be identified by NDC 69680-166-00 and expires Sept. 30, 2026; it was distributed nationwide from Jan. 31 through Sept. 30, 2025. Vitruvias describes the round tablets as off-white to pale brown, possibly flecked, and marked “THY” on one side and “050” on the other.
